Company research
Silo Pharma, Inc.
CIK 1514183Updated Sep 26, 2026
SecuritySILO · NASDAQ · equity
Name history
Uppercut Brands, Inc. · through Aug 14, 2020Point Capital, Inc. · through May 14, 2019Gold Swap Inc · through Jan 7, 2013
SILO price & chart
Loading TradingView…
NASDAQ:SILO on TradingView ↗About the company
We are a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Our therapeutic focus is on developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. We are focused on developing novel therapies that include conventional drugs and psychedelic formulations. The Company’s lead program, SPC-15, is an intranasal drug targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-based loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting the central nervous system with initial research indication in multiple sclerosis (MS).
In the news
Recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
10-Q filing
EFFECT filing
424B3 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 7,605,100Source | 7,411,840Source | 7,746,141Source | 11,642,877Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 217,375Source | 241,215Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,748,700Source | 3,905,799Source | 3,524,308Source | 11,367,034Source |
| Assets, CurrentUSD | 7,387,725Source | 7,111,480Source | 7,681,158Source | 11,572,056Source |
| Prepaid Expense and Other Assets, CurrentUSD | 208,559Source | 30,957Source | 15,970Source | 135,894Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,299,659Source | 2,377,575Source | 1,569,270Source | 1,302,100Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,332Source | 449Source | 316Source | 316Source |
| Additional Paid in CapitalUSD | 25,790,670Source | 20,296,088Source | — | 17,511,589Source |
| Retained Earnings (Accumulated Deficit)USD | -19,492,389Source | -15,264,691Source | -10,871,811Source | -7,171,128Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 5,828Source | 2,419Source | -6,227Source | — |
| Stockholders' Equity Attributable to ParentUSD | 6,305,441Source | 5,034,265Source | 6,176,871Source | 10,340,777Source |
| Liabilities and EquityUSD | 7,605,100Source | 7,411,840Source | 7,746,141Source | 11,642,877Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 650,183Source | 1,655,997Source | 775,590Source | 436,318Source |
| Additional Financial Items | ||||
| Deferred Compensation EquityUSD | — | 0Source | 14,125Source | — |
| Deferred Revenue, CurrentUSD | — | — | 72,102Source | 72,102Source |
| Deferred Revenue, NoncurrentUSD | — | — | 793,680Source | 865,782Source |
| Short-term InvestmentsUSD | 2,110,065Source | 3,174,724Source | 4,140,880Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 117,021Source | 906,773Source | 871,625Source | 577,651Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -4,661,339Source | -3,833,914Source | -3,224,498Source | -3,497,622Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 644,021Source | 973,777Source | -4,147,107Source | 86,707Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 4,860,219Source | 3,241,628Source | -471,121Source | 4,940,948Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 4,748,700Source | 3,905,799Source | 3,524,308Source | 11,367,034Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 37,302Source | 5,084Source | 4,869Source | 2,199Source |
| Income Taxes Paid, NetUSD | — | — | — | 25,159Source |
| Additional Financial Items | ||||
| AmortizationUSD | 11,440Source | 6,185Source | — | — |
| Share-based Payment Arrangement, ExpenseUSD | 117,021Source | — | — | — |
| Amortization of Intangible AssetsUSD | 11,440Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | -14,242Source | — | — |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 169Source | — | — | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | -104,700Source |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | -39,916Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | -4,392,880Source | -3,631,083Source | -3,907,388Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -3,907,388Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -1,163Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | -69,600Source | -1,163Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -3,118Source | -104,700Source |
| InterestExpenseNonoperatingUSD | 37,302Source | 5,084Source | — | — |
| Investment Income, InterestUSD | 207Source | — | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | -331,203Source |
| Net Income (Loss) Attributable to ParentUSD | -4,227,698Source | -4,392,880Source | -3,700,683Source | -3,908,551Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 3,908,551Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -3,908,551Source |
| Nonoperating Income (Expense)USD | 52,964Source | 312,814Source | 224,509Source | -279,732Source |
| Operating ExpensesUSD | 4,308,469Source | 4,771,958Source | 3,921,856Source | 3,693,920Source |
| Other Operating Income (Expense), NetUSD | — | — | — | 84Source |
| Proceeds from Issuance of Common StockUSD | — | 1,673,216Source | — | 4,940,948Source |
| Realized Investment Gains (Losses)USD | 3,911Source | -1,025Source | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | -3,240Source | — | -6,227Source | -331,203Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 72,102Source | 72,102Source | 72,102Source | 72,102Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 390,071Source | 227,259Source |
| Operating Income (Loss)USD | -4,280,662Source | -4,705,694Source | -3,855,592Source | -3,627,656Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -4,227,698Source | -4,392,880Source | -3,631,083Source | -3,907,388Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 3,908,551Source |
| Net Income (Loss) Attributable to ParentUSD | -4,227,698Source | -4,392,880Source | -3,700,683Source | -3,908,551Source |
| Earnings Per Share, BasicUSD per share | -0.5Source | -1.19Source | — | — |
| Earnings Per Share, DilutedUSD per share | -0.5Source | -1.19Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 8,382,272Source | 3,680,389Source | 3,079,874Source | 2,284,240Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 8,382,272Source | 3,680,389Source | 3,079,874Source | 2,284,240Source |
| Interest Expense (non-operating)USD | 37,302Source | 5,084Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 11,440Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | -14,242Source | — | — |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 169Source | — | — | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | -104,700Source |
| Gross ProfitUSD | 27,807Source | 66,264Source | 66,264Source | 66,264Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | -4,392,880Source | -3,631,083Source | -3,907,388Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -4,227,698Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -3,907,388Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | -1.19Source | -1.18Source | -1.71Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | -1.19Source | -1.18Source | -1.71Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -1,163Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | -69,600Source | -1,163Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -3,118Source | -104,700Source |
| Interest ExpenseUSD | — | — | 4,869Source | 2,199Source |
| Investment Income, InterestUSD | 207Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -3,908,551Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | — | — | -3,907,388Source |
| Nonoperating Income (Expense)USD | 52,964Source | 312,814Source | 224,509Source | -279,732Source |
| Operating ExpensesUSD | 4,308,469Source | 4,771,958Source | 3,921,856Source | 3,693,920Source |
| Other ExpensesUSD | — | 50,000Source | — | — |
| Other IncomeUSD | — | — | — | 85,733Source |
| Other Operating Income (Expense), NetUSD | — | — | — | 84Source |
| Realized Investment Gains (Losses)USD | 3,911Source | -1,025Source | — | — |
| Research and Development ExpenseUSD | 2,160,829Source | 2,368,156Source | 845,092Source | 1,286,434Source |
Offerings
Registration 333-291129
Registration 333-286777
- Gross proceeds
- 1999941.8
- Net proceeds
- 1849941.6
- Deal price
- 0.6
- Shares
- 3333236
- Offering price
- $0.600
- Ticker
- SILO
Filing attachments
ea029760202ex4-1.htm · 8-K · 2026-07-13
EX-4.1 2 ea029760202ex4-1.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES A…
Read attachment ↗ea029760202ex4-2.htm · 8-K · 2026-07-13
EX-4.2 3 ea029760202ex4-2.htm FORM OF SERIES A-3 COMMON WARRANT Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECUR…
Read attachment ↗ea029760202ex4-3.htm · 8-K · 2026-07-13
EX-4.3 4 ea029760202ex4-3.htm FORM OF SERIES A-4 COMMON WARRANT Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECUR…
Read attachment ↗ea029760202ex4-4.htm · 8-K · 2026-07-13
EX-4.4 5 ea029760202ex4-4.htm FORM OF PLACEMENT AGENT WARRANT Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURIT…
Read attachment ↗ea029760202ex99-1.htm · 8-K · 2026-07-13
EX-99.1 8 ea029760202ex99-1.htm PRICING PRESS RELEASE DATED JULY 10, 2026 Exhibit 99.1 Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules $4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash SARASOTA, FLA., July 10, 2026 -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a diversified developmental-stage biopharmaceutical company with a ther…
Read attachment ↗ea029533901ex99-1.htm · 8-K · 2026-06-18
EX-99.1 2 ea029533901ex99-1.htm PRESS RELEASE OF SILO PHARMA, INC. DATED JUNE 18, 2026 Exhibit 99.1 Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement SARASOTA, FLA., June 18, 2026 - Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing …
Read attachment ↗